Vaccines Market worth USD 58.4 Billion by 2024 | Latest Innovation, Advance Technology, Top Companies
According to Market Study Report, Vaccines Market provides a comprehensive analysis of the Vaccines Market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities of global industry. This report also provides market landscape and market share information in the Vaccines Market. An exclusive data offered in this report is collected by research and industry experts team.
Get Instant Free Sample Copy in PDF Format @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=267258
The Global Vaccines Market is projected to reach US$ 58.4 Billion by 2024 from US$ 41.7 Billion in 2019, at a CAGR of 7.0% during the forecast period. The report spread across 189 Pages, profiling 15 companies and supported with 108 tables and 35 figures is now available in this research.
Top Companies profiled in the Vaccines Market:
GlaxoSmithKline plc (UK)
Pfizer Inc. (US)
Sanofi Pasteur (France)
Merck & Co. Inc. (US)
CSL Limited (Australia)
Emergent BioSolutions Inc. (US)
Johnson & Johnson (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Panacea Biotec (India)
Biological E (India)
Sinovac Biotech Ltd (China)
Incepta Vaccine LTD. (Bangladesh)
Valneva SE (France)
VBI Vaccines Inc. (US)
Bio Farma (Brazil)
Coupon Code Available for 20% Discount on Website @ https://www.reportsnreports.com/purchase.aspx?name=267258
“The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period.”
On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018.
“By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019.”
On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.
“The market in Asia is projected to witness the highest growth rate during the forecast period (2019–2024).”
Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.
Breakdown of primary participants’ profile:
By Company Type: Tier 1: 47%, Tier 2: 26%, and Tier 3: 27%
By Designation: C-level: 33%, Director-level: 21%, and Others: 46%
By Region: North America: 36%, Europe: 31%, Asia: 16%, and the RoW: 17%
Reason to access this report:
Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.